Oral administration of PF-01247324, a subtype-selective Nav1.8 blocker, reverses cerebellar deficits in a mouse model of multiple sclerosis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Shields, Shannon D ^a,c   Butt, Richard P ^b   Dib Hajj, Sulayman D ^a,c   Waxman, Stephen G ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; PF 01247324; SODIUM CHANNEL NAV1.8; UNCLASSIFIED DRUG; SCN10A PROTEIN, MOUSE; VOLTAGE GATED SODIUM CHANNEL BLOCKING AGENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; BRAIN DYSFUNCTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GRIP STRENGTH; MOTOR COORDINATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; PURKINJE CELL; WILD TYPE; ANIMAL; GENETICS; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ADMINISTRATION, ORAL; ANIMALS; HUMANS; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; NAV1.8 VOLTAGE-GATED SODIUM CHANNEL; PURKINJE CELLS; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS;

EID: 84929079871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119067     Document Type: Article

References (20)

1. Waxman SG. Ion channels and neuronal dysfunction in multiple sclerosis. Arch Neurol. 2002; 59:1377-1380. PMID: 12223023
2. Eijkelkamp N, Linley JE, Baker MD, Minett MS, Cregg R, Werdehausen T, et al. Neurological perspectives on voltage-gated sodium channels. Brain 2012; 135:2585-2612. doi: 10.1093/brain/aws225 PMID: 22961543
3. Black JA, Dib-Hajj S, Baker D, Newcomb J, Cuzner ML, Waxman SG. Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. Proc Natl Acad Sci U S A 2000; 97:11598-11602. PMID: 11027357
4. Renganathan M, Gelderblom M, Black JA, Waxman SG. Expression of Nav1.8 sodium channels perturbs the firing patterns of cerebellar Purkinje cells. Brain Res 2003; 959:235-242. PMID: 12493611
5. Saab CY, Craner MJ, Kataoka Y, Waxman SG. Abnormal Purkinje cell activity in vivo in experimental allergic encephalomyelitis. Exp Brain Res 2004; 158:1-8. PMID: 15118796
6. Shields SD, Cheng X, Gasser A, Saab CY, Tyrrell L, Eastman EM, et al. A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis. Ann Neurol 2012; 71:186-194. doi: 10.1002/ana.22665 PMID: 22367990
7. England S, Payne L, Krajewski J, Stoehr S, Liu H, Rees H, et al. In vitro characterization of two novel selective Nav1.8 modulators. Program No. 359.6. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009, Online.
8. Payne CE, Brown AR, Theile JW, Loucif AJC, Alexandrou AJ, Fuller MD, et al. A novel selective and orally bioavailable NaV1.8 blocker PF-01247324 attenuates nociception and sensory neuron excitability. Brit J Pharmacol. 2015; In Press
9. Lo AC, Saab CY, Black JA, Waxman SG. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 2003; 90:3566-3571. PMID: 12904334
10. Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev 2007; 1:CD005029. PMID: 17253537
11. Swingler RJ, Compston DA. The morbidity of multiple sclerosis. Q J Med 1992; 83:325-337. PMID: 1631264
12. Espir ML, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol). J Neurol Neurosurg Psychiatry 1970; 33:528-531. PMID: 5505682
13. Ramsaransing G, Zwanikken C, De Keyser J. Worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ 2000; 320:1113. PMID: 10775222
14. Solaro C, Brichetto G, Battaglia MA, Messmer UM, Mancardi GL. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurol Sci 2005; 25:307-310. PMID: 15729492
15. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9:681-688. doi: 10.1016/S1474-4422(10)70131-9 PMID: 20621711
16. Bostock H, Sears TA. The internodal axon membrane: electrical excitability and continuous conduction in segmental demyelination. J Physiol 1978; 280:273-301. PMID: 690876
17. Foster RE, Whalen CC, Waxman SG. Reorganization of the axon membrane in demyelinated peripheral nerve fibers: morphological evidence. Science 1980; 210:661-663. PMID: 6159685
18. Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Waxman SG. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci U S A 2004; 101:8168-8173. PMID: 15148385
19. Waxman SG. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci 2001; 7:932-941.
20. Waxman SG, Brill MH. Conduction through demyelinated plaques in multiple sclerosis: computer simulations of facilitation by short internodes. J Neurol Neurosurg Psychiatry 1978; 41:408-416. PMID: 660202